Subjects was Grouped for Clinical Test on the Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Another Key Product of AIM Vaccine
Bivalent Delta Omicron BA.5 mRNA COVID-19 Vaccine was Approved for Phase-III Clinical Test in Pakistan
Expanded Shanghai-Hong Kong Connect Stocks and the Notice Will Take Effect from Next Monday
Two Types of mRNA COVID-19 Vaccines Produced by AIM Vaccine was Approved for Clinical Test in Pakistan
Rongan Biological was Selected on the List of Specialized, Refined, Differentiated and Innovative “Little Giant” Key Incubation Enterprises in Ningbo in 2023
AIM Vaccine Joins Hands with Fortune Global 500 Enterprises to Create the Global Industrial Highland for “Intelligent Manufacturing of New Medicine” in Beijing Economic-Technological Development Area
EV71-CA16 BIVALENT HFMD VACCINE CANDIDATE OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
FREEZE-DRIED HUMAN RABIES VACCINE CANDIDATE (SERUM-FREE VERO CELL) OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Phase II Clinical Data on AIM’s mRNA Impressive and Significantly Effective On Omicron
Upgrade for Higher Safety ▏AIM Rong’an Submitted Clinical Application for Serum-free Human Rabies Vaccine to CDE
Hardcore Technology ▏AIM Convac Submitted Clinical Application for EV71-CA16 HFMD Vaccine (HDC) to CDE
Rising Star of International First-line Vaccine ▏AIM Vaccine MCV4 Obtained Clinical Approval
R&D of vaccine targeted at COVID-19 Delta variant has been incorporated into “Pioneer Program” of Zhejiang Province for rolling submission to CDE.
AIM MCV4 vaccine clinical application has been accepted for CDE approval, coming into the frontiers
13v combined pneumococcal polysaccharide vaccine of AIM Vaccine has obtained phase-3 clinical ethical approval
Phase-1 clinical test for mRNA COVID-19 vaccine of AIM Vaccine is in smooth progress, manifesting a high safety and tolerance
AIM Vaccine enlisted for important contracted project for “Two-zone” construction in Beijing with introduced investments
Advanced Innovation and R&D Platform
· We are in possession of 5 authenticated technical platforms of vaccines for human use. Each platform is provided with at least one vaccine product subjecting to commercialization or development.
· 22 innovative vaccines under development are targeted at 13 diseases.
· Products under production and development cover top 10 vaccine products worldwide (global sales statistics for the year of 2020), enjoying a large market space.
· One of the first manufacturing enterprises with P3 laboratory in China according to the 14th Five-Year Plan for National Economic and Social Development.
PCV13 vaccine under development for phase-3 clinical test can satisfy deficient market demands in China. As compared with similar products in the market, this product has manifested its superior advantages according to preliminary clinical research. PCV20 under development is expected to be the first 20v pneumococcal polysaccharide vaccine in China. PPSV23 vaccine under development also has a high market potential, which can be offered to people of different ages and income in together with PCV13 and PCV20 owing to its coupling availability.
EV71-CA16 bivalent HFMD
The first EV71-CA16 bivalent HFMD vaccine under development worldwide belongs to a potential innovative bivalent HFMD vaccine targeted at EV71 and CA16 viral strains for the first time in the world.
Meningococcal Conjugate Group A, C, Y and W135 Vaccine
Meningococcal Conjugate Group A, C, Y and W135 Vaccine (MCV4) is available for inoculation for children below the age of 2 to induce immune response. It has a high market potential as there is no other group A, C, Y and W135 meningococcal polysaccharide vaccine (MCV4) approved in the market.
COVID-19 Vaccine Portfolio
COVID-19 vaccine combinations under development are in 3 technical routes, which can cover numerous variants, and improve the success rate. Meanwhile, they are also provided with flexible sequential regimen. Such vaccine combinations include mRNA COVID-19 vaccine，broad-spectrum COVID-19 vaccine that is under development based on adenovirus vectors and so on.
DTP vaccine combination
In such vaccine combination, DTap is the leading product in China’s DTP vaccine market at present. As a leading vaccine product, DTcp has not been approved yet in China. DTP-hib is expected to become one of combined vaccine products as listed in China for prevention of the most diseases.
Rabies vaccine combination under development for human use
Such combination covers the globally innovative mRNA rabies vaccine under development, human diploid cell based rabies vaccine for human use as characterized by minimum inoculation, simple production technique, easy storage and stable quality as well as rabies vaccine for human use that uses serum free Vero cells. It features in higher safety and immunogenicity as well as less side effect.
As compared with traditional chicken embryo cultured influenza vaccine, 4v influenza vaccine (MDCK cell) is provided with higher safety. As the first potential product globally developed, universal influenza vaccine has more extensive protection effect, which can resist all types of influenza viral strains.
HKSE Market Value（million）
Spot Price (HKD)
Highest Today (HKD)
Lowest Today (HKD)
We acquired 50.1546% equities of Liverna to further accelerate research of mRNA COVID-19 vaccine and production layout.
We completed restructuring, and changed to corporate name to AIM Vaccine Co., Ltd.
In the same year, we acquired 49% equities of AIM Explorer and 20% equities of Rong’an Biology. Thus, AIM Explorer and Rong’an Biology became two wholly owned subsidiaries of AIM Vaccine.
We obtained approval of new drug application for MPSV4 in October, 2018.
We obtained GMP certificate as required by production of MPSV4 in December, 2018.
During the period from September, 2017 to January, 2019, we acquired all equities of AIM Weixin. As a result of it, AIM Weixin became a wholly owned subsidiary of AIM Vaccine.
AIM Weixin obtained approval of new drug application for vaccine targeted at hemorrhagic fever with renal syndrome in September, 2007 and GMP certificate as required by production in February, 2008. Previously, it also obtained approval of new drug application for mumps vaccine in October, 2004 and GMP certificate as required by production of the same vaccine in January, 2005.
We acquired all equities of AIM Kanghuai during the period from November, 2016 to December, 2017. As a result of it, AIM Kanghuai became a wholly owned subsidiary of AIM Vaccine.
AIM Kanghuai obtained approval of new drug application for HBV vaccine inactivated (human diploid cell) in April, 2015. Later, it obtained approval from National Medical Products Administration for production of other types of HBV vaccines inactivated (human diploid cell) in January, 2016.
We acquired entire equity interests of AIM Honesty
AIM Honesty respectively obtained NDA for 10ug/0.5ml and 20ug/0.5ml recombinant HBV vaccine (Hansenula Polymorpha) from National Medical Products Administration in March, 2004 and August, 2013, and obtained GMP production certificate in June, 2004.
AIM Vaccine is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from R&D, manufacturing and commercialization. In 2020, the company realized lot release of 60 million dosages with vaccine products distributed to 31 provinces, autonomous regions and municipalities directly under the Central Government in China. AIM Vaccine is in possession of 5 authenticated platform technologies on human vaccine. This serves as an important guarantee for R&D speed and flexibility. Presently, the company has 8 commercialized vaccines targeted at 6 diseases and 22 innovative vaccines under development as targeted at 13 diseases. Products under production and development cover top 10 vaccine products worldwide (global sales statistics for the year of 2020).
Through ten-year development, the company has established its business mode and corporate culture as characterized by inclusiveness and sustainable exploration. As a result of it, its existing businesses have been further expanded and optimized. Presently, the company has 4 authenticated wholly owned vaccine manufacturing enterprises affiliated to it, namely AIM Honesty, AIM Kanghuai, AIM Weixin and Rong’an Bio. The company holds controlling shares of 3 research institutes, including a R&D center, AIM Explorer as established in 2018 for provision of technical supports for initial and advanced researches by R&D departments of various plants. In 2021, AIM completed merger and acquisition of Liverna Therapeutics Inc. It is one of 3 enterprises acquired clinical trial approval of mRNA COVID-19 vaccine in China, which has established its own mRNA production and drug express delivery platform.
AIM Vaccine Corporation has always been adhering to the mission of “developing and manufacturing top quality vaccines to safeguard the health of the world” through strict control of vaccine quality. It prides itself on a professional and devoted sales team consisting of more than 100 members with over a decade of pharmaceutical or vaccine sales experience, and a core business leadership team with an average of 12 years of vaccine commercialization experience at transnational pharmaceuticals as well as outstanding achievements in marketing international blockbuster vaccines (including the world’s first HPV, IPV and DTaP-IPV-Hib vaccines). Currently, products available for sale mainly include recombinant hepatitis B vaccine (hansenula polymorpha), rabies vaccine (Vero Cell) for human use,freeze-dried, hepatitis A vaccine (human diploid cell), inactivated, mumps vaccine, live, haemorrhagic fever with renal syndrome bivalent vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine (MPSV4).